Influenza control in the 21st century: Optimizing protection of older adults

Monto, Arnold S.; Ansaldi, Filippo; Aspinall, Richard; McElhaney, Janet E.; Montaño, Luis F.; Nichol, Kristin L.; Puig-Barberà, Joan; Schmitt, Joe; Stephenson, Iain

doi:10.1016/j.vaccine.2009.06.032

Cited by 110 publications

(70 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[7][8][9][10][11] Finally, another aspect that heavily affects influenza vaccine diffusion and uptake is its sub-optimal tolerability and acceptability. A well-established barrier to influenza immunization is a general lack of patient acceptance of traditional intramuscular vaccination: recent studies have demonstrated that the most common reasons for missing previous vaccinations are fear of adverse events, bothered by pain during injection and dislike for injections or needles, and that other ways of vaccine administration were considered to be an encouraging alternative to implement vaccination against influenza.…”

Section: Head-to-head Comparison Of An Intradermal and A Virosome Infmentioning

confidence: 99%

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60

Ansaldi

Orsi

Florentiis

et al. 2013

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Section: Head-to-head Comparison Of An Intradermal and A Virosome Infmentioning

confidence: 99%

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60

Ansaldi

Orsi

Florentiis

et al. 2013

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

“…These vaccines may offer a short-term solution, although further research is required to exploit the many other new technologies. 68 No data are available to recommend LAIV in older adults.…”

Section: Influenza Vaccinationmentioning

confidence: 99%

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)

Esposito

Bonanni

Maggi

et al. 2016

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Rapid population aging has become a major challenge in the industrialized world and progressive aging is a key reason for making improvement in vaccination a cornerstone of public health strategy. An increase in age-related disorders and conditions is likely to be seen in the near future, and these are risk factors for the occurrence of a number of vaccine-preventable diseases. An improvement in infectious diseases prevention specifically aimed at adults and the elderly can therefore also decrease the burden of these chronic conditions by reducing morbidity, disability, hospital admissions, health costs, mortality rates and, perhaps most importantly, by improving the quality of life. Among adults, it is necessary to identify groups at increased risk of vaccine-preventable diseases and highlight the epidemiological impact and benefits of vaccinations using an evidence-based approach. This document provides clinical practice guidance on immunization for adults in order to provide recommendations for decision makers and healthcare workers in Europe. Although immunization is considered one of the most impactful and cost-effective public health measures that can be undertaken, vaccination coverage rates among adults are largely lower than the stated goal of 95% among adults, and stronger efforts are needed to increase coverage in this population. Active surveillance of adult vaccine-preventable diseases, determining the effectiveness of the vaccines approved for marketing in the last 5 y, the efficacy and safety of vaccines in immunocompromised patients, as well as in pregnant women, represent the priorities for future research.

show abstract

“…New formulations already tested on older individuals include increasing the TIV dosage (60 g versus 15 g of HA) (Cate et al, 2009;Falsey et al, 2009); changes in the type of vaccine (live attenuated vaccines (LAVs) (De Villiers et al, 2009); virosomal vaccines (Huckriede et al, 2005); and adjuvanted vaccines with MF59 or AS03) (de Bruijn et al, 2006;Pegliasco et al, 2001;Roman et al, 2010;Leroux-Roels et al, 2010). Further formulation changes which are at early stages of development include enhancing adjuvantation of current vaccines (Keitel et al, 2008) or the development of novel adjuvant as the labile enterotoxin from E. coli, placed over the immunization site in a patch (Glenn et al, 2009); the use of life attenuated influenza vaccines (LAIVs) in combination with current vaccines (Monto et al, 2009); DNA vaccines (Drape et al, 2006) and recombinant vaccines (Cox and Hollister, 2009;Treanor et al, 2007); the use of different modes of delivery the viral antigens have been assessed such as intradermal (Holland et al, 2008;Leroux-Roels et al, 2008); and alternative antigens (use of highly conserved maturational cleavage site of HA precursor, the external domain of the M2 protein, and the nucleoprotein) (Bianchi et al, 2005;Livingston et al, 2006).…”

Section: What Do We Improve: the Vaccine Or The Immune Response?mentioning

confidence: 99%

“…The highest prevalence mainly occurs amongst older adults especially those with chronic medical conditions or immunological disorders, resulting in increased mortality in these high risk groups (World Health Organization, 2005). However, mortality is just the tip of the iceberg in terms of disease burden, as it can also act as a trigger for functional decline leading to disability in some aged individuals (Monto et al, 2009;McElhaney, 2005;Greenberg and Piedra, 2004;Gavazzi and Krause, 2002). Such outcomes represent a considerable economic burden amounting to $87 billion each year in the United States (Molinari et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Vaccine effectiveness in older individuals: What has been learned from the influenza-vaccine experience

Lang

Govind

Mitchell

et al. 2011

Ageing Research Reviews

Self Cite

View full text Add to dashboard Cite

a b s t r a c tVaccination policies in most high-income countries attempt to reduce the adverse impact of influenza targeting people aged at least 60 years. However, while it is widely believed that the current immunization strategy saves many lives, influenza infection still remains a severe burden in aged individuals leading to a wide debate on the exact magnitude of the benefit of vaccination in this population. The first aim of the present review is to examine how effective current influenza-vaccine strategies are in aged adults, by analysing which are the most important factors modulating the interpretation of study results in this population. Furthermore, consideration will be given to how immune factors influence the measurement of vaccine efficacy/effectiveness, where advancing age leads to deleterious changes in the adaptive immune system, resulting in less than optimal responses to infectious agents and vaccination. Finally this review concludes with possible strategies to improve the ability of the senescent immune system to respond to vaccination.

show abstract

Influenza control in the 21st century: Optimizing protection of older adults

Cited by 110 publications

References 101 publications

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)

Vaccine effectiveness in older individuals: What has been learned from the influenza-vaccine experience

Contact Info

Product

Resources

About